Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 4

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 4
---
 upon our current management’s capabilities and the future talent we may attract, we plan to retain rights to internally develop and commercialize products; however, we may seek collaborations with partners in the biopharmaceutical industry when a partnering strategy serves to maximize value for our stockholders.

Product Candidate Pipeline:

Product CandidateTarget Indication(s)Development PhaseEstimated Global Market SizeART27.13 – Synthetic Dual Cannabinoid GPCR AgonistCancer-related anorexia ClinicalCancer anorexia cachexia syndrome: >$2 billionART26.12 – FABP5 inhibitor CIPN, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disordersClinical CIPN: >$1 billionProstate cancer: approximately $9 billionBreast cancer: approximately $18 billionPsoriasis: $12 billionPTSD: approximately $7 billion ART12.11 – Synthetic CBD Cocrystal Anxiety, depression, PTSD, and other potential indications Pre-clinicalAnxiety disorders: >$11 billionPTSD: approximately $7 billion

 6Table of contents

Background

Emerging science suggests that modulating lipid-signaling pathways can unlock novel therapeutic strategies for diseases and medical conditions for which there are no or limited options. Lipids are critical to certain cell signaling pathways. Lipid-signaling modulation is the alteration of the signaling of lipid molecules to change biological activity or function within cellular communication pathways. Lipids contain various fatty acids as their building blocks and are the key components of lipid activity. Fatty Acid Binding Proteins (FABPs) facilitate lipid-signaling by binding to fatty acids which control various cellular functions. FABPs are essential mediators of normal cell signaling processes and under certain conditions can be associated with dysfunctional signaling. Inhibition of specific FABPs may correct abnormal lipid-signaling or improve the function of the ECS, which holds promise as new treatment modalities. Our Company is at the forefront of advancing the application of lipid-modulating therapeutics.

The ECS is composed of cannabinoid receptors, endogenous receptor ligands (“endocannabinoids”) and their associated transporter mechanisms, as well as enzymes responsible for the synthesis and degradation of endocannabinoids and has emerged as a considerable target for pharmacotherapy approaches of numerous human diseases. As a widespread modulatory and lipid-signaling system, the ECS plays important roles in the CNS, development, synaptic plasticity, and the response to endogenous and environmental factors.

The modulation of the ECS can be affected by using selective or non